Z6尊龙·凯时(中国)

SMO Services & Solutions

▪ About SMO ClinPlus

ClinPlus provides site management services to both local and global companies in research development in pharmaceuticals, medical devices, and health-related products. Since its establishment in 2009, ClinPlus has been committed to undertaking clinically valued innovative drugs projects. It has participated in over 2800 SMO projects and has covered 24 medical units in total, including tumors, endocrine diseases, medical devices, viral hepatitis, immune diseases, blood diseases, infection and more. It has also brought into the market over 90 drugs domestically and worldwide. Provide high quality site management service for well-known pharmaceutical companies including MSD, PXL, Akesobio, Zelgen, Novartis, Hengrui, Bristol-Myers Squibb, Henlius, Eli Lilly, and Labcorp.

▪ Site/Resource Coverage

As of Sep 30, 2023, ClinPlus has more than 3,900 professionals serving over 850 clinical trial research institutions, out of the 1,300 ones it is able to cover. ClinPlus is able to fulfill the needs of our clients in most projects by being able to provide services in about 180 cities in most provinces across the country.

Unblinded BU
Urinary Tumors BU
Digestive Oncology BU
Phase I BU
SSU BU
Blood Tumors BU
CART BU
Gastroenterology BU

Gynecology BU
Immunodermatolog BU
Pediatrics BU
Cardiovascular BU
Endocrine BU
Lung Cancer BU
Hepatopathy BU
Respiratory BU

Breast Cancer BU
Antibiotics BU
ICU BU
Neurology & Neurosurgery BU
Psychiatry BU
Medical Device & Surgical BU
Ophthalmology & Otorhinolaryngology BU

▪ Core Market

From the therapeutic perspective
We cover the mainstream disease spectrum, such as tumor, endocrine, cardiovascular, respiratory, virus, etc.
From the perspective of clinical trial stages
We are involved in Phase I-III and post-marketing surveillance
From the client's perspective
Clients include world-renowned new drug R&D companies, CRO companies, and most domestic new drug companies and mainstream pharmaceutical companies.

▪ Achievements

2015 ：
ClinPlus was awarded the first PD-1 project in China: Bristol-Myers Squibb's research in Navulamumab for treating lung cancer;
2016 ：
ClinPlus was awarded the first CAR-T project: JW's Therapeutics's research in CD19 compound antigen receptor T cell injection for treating B-cell non-Hodgkin lymphoma;
2018 ：
The first monoclonal antibody drug in China for treating hyperlipidemia-Rebbegan by Amgen Biotech, awarded to ClinPlus, was successfully listed in the market;
2019 ：
The first direct oral anti-hepatitis C virus drug, Sofosbuvir tablets, awarded to ClinPlus, was approved to be sold in the market.

The world's first approved biologic Beliuximab for treating systemic lupus erythematosus, awarded to ClinPlus, was approved to be sold in the market.

The first domestic human papillomavirus vaccine in China-Xinkonin, awarded to ClinPlus, was approved to be sold in the market.
2022 ：
ClinPlus assisted sponsor to get NDA for the world's first and only approved ADC drug targeting Trop-2, the first domestic double antibody and the world's first PD-1/CTLA-4 double antibody and other innovative drugs.

▪ Four modules of model establishment

Purpose：

To form a model by fully integrating previous performances in operation, including site selection, SSU, patient enrollment, risk management, quality control, database, investigators' fee, patient expenses. By establishing a relatively realistic and reliable model during the start of the project, we can help our clients find a more robust and practical implementation plan to improve efficiency and maximize the benefits of resource allocation.

▪ Corporate Social Responsibility